{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:36:35Z","timestamp":1775514995176,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20<jats:sup>+<\/jats:sup>) B-cell lymphoma, who achieved a complete response\/unconfirmed complete response after standard treatments. Patients were randomized (1:1) to receive IBI301 or rituximab (375\u00a0mg\/m<jats:sup>2<\/jats:sup>, IV). Patients who continuously benefitted from the trial after the PK phase underwent the extension phase to receive up to three cycles of 3-month-cycle of rituximab\/IBI301 maintenance therapy. PK was described using the area under the serum concentration\u2013time curve from time zero to infinity (AUC<jats:sub>0-inf<\/jats:sub>), AUC from time zero to last quantifiable concentration (AUC<jats:sub>0-t<\/jats:sub>), and maximum serum concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>). Pharmacodynamics (PD), incidence of adverse events and immunogenicity were evaluated. PK was defined equivalent, if 90% confidence intervals (CIs) for geometric mean ratios of PK endpoints fell within the margin of 0.8\u20131.25. Overall, 181 patients were enrolled in IBI301 (<jats:italic>n<\/jats:italic>\u2009=\u200989) and rituximab (<jats:italic>n<\/jats:italic>\u2009=\u200992) groups. Geometric mean ratios of AUC<jats:sub>0-inf<\/jats:sub>, AUC<jats:sub>0-t<\/jats:sub>, and <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> were 0.91 (90% CI 0.85, 0.97), 0.91 (90% CI 0.86, 0.97), and 0.96 (90% CI 0.92, 1.01) between treatment groups, all within the bioequivalence range. Peripheral CD19<jats:sup>+<\/jats:sup> and CD20<jats:sup>+<\/jats:sup> B-cell counts were similar at each prespecified time point between the groups. No difference in immunogenicity was observed. The incidences of treatment-emergent adverse events (84.3% vs. 83.5%) and treatment-related AEs (56.2% vs. 61.5%) were comparable (IBI301 vs. rituximab). IBI301 was PK bioequivalent to rituximab in patients with CD20<jats:sup>+<\/jats:sup> B-cell lymphoma. The PD, safety, and immunogenicity profiles of IBI301 were similar to those of rituximab.<\/jats:p>","DOI":"10.1038\/s41598-020-68360-0","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:04:02Z","timestamp":1594807442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study"],"prefix":"10.1038","volume":"10","author":[{"given":"Bo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xielan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"68360_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"68360_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11912-019-0792-4","volume":"21","author":"R Hu","year":"2019","unstructured":"Hu, R., Winter, A. & Hill, B. T. The emerging role of minimal residual disease testing in diffuse large B-cell lymphoma. Curr. Oncol. Rep. 21, 44 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"68360_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JBM.S190784","volume":"10","author":"R Mohammed","year":"2019","unstructured":"Mohammed, R., Milne, A., Kayani, K. & Ojha, U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas. J. Blood Med. 10, 71\u201384 (2019).","journal-title":"J. Blood Med."},{"key":"68360_CR4","doi-asserted-by":"publisher","first-page":"204062072090289","DOI":"10.1177\/2040620720902899","volume":"11","author":"PA Riedell","year":"2020","unstructured":"Riedell, P. A. & Bishop, M. R. Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Ther. Adv. Hematol. 11, 2040620720902899 (2020).","journal-title":"Ther. Adv. Hematol."},{"key":"68360_CR5","doi-asserted-by":"publisher","first-page":"3762864","DOI":"10.1155\/2018\/3762864","volume":"2018","author":"M Greenwald","year":"2018","unstructured":"Greenwald, M., Tesser, J. & Sewell, K. L. Biosimilars have arrived: rituximab. Arthritis 2018, 3762864 (2018).","journal-title":"Arthritis"},{"key":"68360_CR6","unstructured":"Roche. Roche reports positive studies of mabThera given by subcutaneous injection (Accessed 8 December 2012); https:\/\/www.roche.com\/media\/releases\/med-cor-2012-12-08b.htm (2012)."},{"key":"68360_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-016-2523-7","volume":"16","author":"J Wu","year":"2016","unstructured":"Wu, J. et al. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. BMC Cancer 16, 537 (2016).","journal-title":"BMC Cancer"},{"key":"68360_CR8","first-page":"77900135","volume":"11","author":"A Phillippidis","year":"2014","unstructured":"Phillippidis, A. Biosimilars: 11 drugs to watch. Genet. Eng. Biotechnol. News 11, 77900135 (2014).","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"68360_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","volume":"44","author":"R Alten","year":"2015","unstructured":"Alten, R. & Cronstein, B. N. Clinical trial development for biosimilars. Semin. Arthritis Rheum. 44, S2-8 (2015).","journal-title":"Semin. Arthritis Rheum."},{"issue":"Suppl 1","key":"68360_CR10","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1053\/j.seminoncol.2013.12.002","volume":"41","author":"LA Bui","year":"2014","unstructured":"Bui, L. A. & Taylor, C. Developing clinical trials for biosimilars. Semin. Oncol. 41(Suppl 1), S15-25 (2014).","journal-title":"Semin. Oncol."},{"key":"68360_CR11","first-page":"1234","volume":"23","author":"A Hung","year":"2017","unstructured":"Hung, A., Vu, Q. & Mostovoy, L. A systematic review of U.S. biosimilar approvals: what evidence does the FDA require and how are manufacturers responding?. J. Manag. Care Spec. Pharm. 23, 1234\u20131244 (2017).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"68360_CR12","unstructured":"US Department of Health and Human Services and Federal Register. Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments, Washington, D.C. (2010)."},{"key":"68360_CR13","unstructured":"Generics and Biosimilars Initiative (GaBI) Online. Biosimilars of rituximab. https:\/\/gabionline.net\/Biosimilars\/General\/Biosimilars-of-rituximab. Accessed 20 July 2018."},{"key":"68360_CR14","first-page":"320","volume":"39","author":"B Jiang","year":"2018","unstructured":"Jiang, B. et al. Tolerance and pharmacodynamics phase clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin\u2019s lymphoma. Zhonghua Xue Ye Xue Za Zhi 39, 320\u2013324 (2018).","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"68360_CR15","unstructured":"Genentech Inc. Rituxan\u00ae (Rituximab) Prescribing Information, 2013."},{"key":"68360_CR16","unstructured":"Hoffmann-La Roche Ltd. MabThera (Rituximab) Summary of Product Characteristics (2009)."},{"key":"68360_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17, 1244 (1999).","journal-title":"J. Clin. Oncol."},{"key":"68360_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2344317","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto, R. & Peto, J. Asymptotically efficient rank invariant test procedures. J. R. Stat. Soc. Ser. A (General). 135, 185\u2013198 (1972).","journal-title":"J. R. Stat. Soc. Ser. A (General)."},{"key":"68360_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1541-0420.2009.01243.x","volume":"66","author":"S Yang","year":"2010","unstructured":"Yang, S. & Prentice, R. Improved logrank-type tests for survival data using adaptive weights. Biometrics 66, 30\u201338 (2010).","journal-title":"Biometrics"},{"key":"68360_CR20","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","volume":"5","author":"M Ogura","year":"2018","unstructured":"Ogura, M. et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 5, e543\u2013e553 (2018).","journal-title":"Lancet Haematol."},{"key":"68360_CR21","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak, W. et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 4, e350\u2013e361 (2017).","journal-title":"Lancet Haematol."},{"key":"68360_CR22","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","volume":"4","author":"WS Kim","year":"2017","unstructured":"Kim, W. S. et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 4, e362\u2013e373 (2017).","journal-title":"Lancet Haematol."},{"key":"68360_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","volume":"81","author":"M Candelaria","year":"2018","unstructured":"Candelaria, M. et al. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother. Pharmacol. 81, 515\u2013527 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"68360_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","volume":"78","author":"V Gota","year":"2016","unstructured":"Gota, V. et al. Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother. Pharmacol. 78, 353\u2013359 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"68360_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-019-00376-z","volume":"33","author":"S Lee","year":"2019","unstructured":"Lee, S., Lee, H. & Kim, E. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin\u2019s lymphoma: a systematic review and meta-analysis. BioDrugs 33, 469\u2013483 (2019).","journal-title":"BioDrugs"},{"key":"68360_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40259-016-0171-8","volume":"30","author":"HA Cuello","year":"2016","unstructured":"Cuello, H. A. et al. Comparability of antibody-mediated cell killing activity between a proposed biosimilar RTXM83 and the originator rituxima. Biodrugs 30, 225\u2013231 (2016).","journal-title":"Biodrugs"},{"key":"68360_CR27","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00520-017-3747-z","volume":"25","author":"M Yokoyama","year":"2017","unstructured":"Yokoyama, M. et al. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan. Support Care Cancer 25, 3313\u20133320 (2017).","journal-title":"Support Care Cancer"},{"key":"68360_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EM van Brummelen","year":"2016","unstructured":"van Brummelen, E. M., Ros, W., Wolbink, G., Beijnen, J. H. & Schellens, J. H. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 21, 1260\u20131268 (2016).","journal-title":"Oncologist."},{"key":"68360_CR29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/j.1349-7006.2011.02001.x","volume":"102","author":"K Tobinai","year":"2011","unstructured":"Tobinai, K. et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci. 102, 1698\u20131705 (2011).","journal-title":"Cancer Sci."},{"key":"68360_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik, P. et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198\u2013206 (2014).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68360-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68360-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:05:15Z","timestamp":1670335515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68360-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68360"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68360-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hui Zhou, Jie Yu and Xing Sun are employees of Innovent Biologics, Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11676"}}